Tempus AI’s 11% Surge: Short Squeeze, AI Cancer Breakthrough, and a Deal That Could Die Tomorrow

Posted on by

(SeaPRwire) –   By: Lucas Caldwell

Tempus AI’s stock didn’t just climb 11% Friday—it exploded. The $50.95 price tag isn’t just a win for investors. It’s a perfect storm: a top-tier AI cancer detection tool, a short squeeze waiting to happen, and sector momentum from a peer’s strong earnings. This isn’t your average tech rally—every catalyst is tied to survival or growth for the company.

Let’s cut to the numbers. TEM traded at $50.95, outpacing Nasdaq’s 0.86% and healthcare’s 0.3% gains. PRISM2, their AI model, landed in Nature Medicine as a best-in-class cancer detector. Over 30% of the float was shorted—so when the good news hit, shorts scrambled to cover, amplifying the surge.

There’s more. Tempus posted its first quarterly profit ever and raised full-year revenue guidance. Doximity, a peer, beat Q1 revenue estimates ($156.6M vs $151.7M) and talked up AI’s upside. CellCarta also teamed up with Tempus for oncology companion diagnostics—adding another layer to their credibility.

The AI healthcare sector is heating up. Doximity’s CEO said AI is “up-leveling” their business, and that kind of buzz lifts everyone. Investors are hungry for AI wins that actually translate to real results—like PRISM2’s clinical validation. Tempus is riding that wave, but it’s not all smooth sailing.

The Personalis acquisition hangs by a thread. The deal dies if TEM falls below $46. Friday’s rally gives a cushion, but technicals are mixed: 5% above 20-day SMA ($48.15) but 13% below 200-day ($58.31). The 50-day SMA ($51.11) is just ahead—if they break that, momentum holds. If not, watch out.

If TEM can’t stay above $46 for the next quarter, the Personalis deal collapses, and the short squeeze reverses so fast it’ll make your head spin.

Author bio: Lucas Caldwell, a tech opinion leader with millions of followers on X/Twitter, focusing on AI and healthcare market trends.